Hereditary Angioedema Market

The hereditary angioedema market was valued at USD 3.5 billion in 2023, driven by rising hereditary angioedema prevalence, advancements in genetic research, increased awareness and early diagnosis, a focus on prophylactic treatments, and regulatory support for rare disease therapies. It is expected to grow at a CAGR of 7.4% during the period 2024-2032 and likely to reach a market value of USD 6.7 billion by 2032.

Hereditary Angioedema Market Analysis

Hereditary angioedema is a rare genetic disorder characterised by sudden, recurrent episodes of severe swelling in various parts of the body, including the hands, feet, face, and airways. This condition is often triggered by stress or minor injuries and is caused by a deficiency or dysfunction in the C1 esterase inhibitor, leading to uncontrolled inflammation. Hereditary angioedema can be life-threatening when it affects the airways, making prompt diagnosis and treatment essential. Hereditary angioedema management focuses on preventing and controlling attacks through specialised therapies, such as C1 esterase inhibitors, bradykinin receptor antagonists, and kallikrein inhibitors, which provide relief and improve patients' quality of life.

Market Drivers

• Rising Prevalence of Hereditary Angioedema: The increasing diagnosis of Hereditary angioedema is driving demand for targeted therapies. As awareness of hereditary angioedema grows among healthcare professionals and patients, more individuals are diagnosed, necessitating effective treatments to manage symptoms and prevent life-threatening complications.
• Advancements in Genetic Research: Genetic research is improving understanding of hereditary angioedema, enabling the development of therapies that target the condition’s underlying causes. These advancements are driving pharmaceutical innovation, leading to the introduction of more specific and effective hereditary angioedema treatments, which is expanding the market.
• Increased Awareness and Early Diagnosis: Awareness campaigns and improved diagnostic techniques are contributing to earlier hereditary angioedema diagnoses. Timely diagnosis allows for faster intervention, improving patient outcomes and increasing demand for therapies that help manage and prevent attacks, thus driving market growth.
• Focus on Prophylactic Treatments: There is a growing focus on preventive treatments for hereditary angioedema, with patients and healthcare providers prioritising options that reduce attack frequency. This shift towards prophylactic therapies is driving demand for drugs that offer long-term management, such as C1 esterase inhibitors and kallikrein inhibitors.
• Regulatory Support for Rare Disease Treatments: Regulatory bodies are increasingly supporting rare disease treatments by fast-tracking approvals and providing incentives for orphan drug development. This support encourages pharmaceutical companies to invest in hereditary angioedema treatment research and development, helping to expand the market and bring new therapies to patients more quickly.

Challenges

• Limited Awareness in Developing Regions: In some developing countries, awareness of hereditary angioedema is low, resulting in underdiagnosis and insufficient treatment options. Limited healthcare infrastructure and a lack of knowledge among healthcare providers can hinder timely diagnosis, challenging efforts to expand access to hereditary angioedema treatments globally.
• Adverse Effects of Current Therapies: Some hereditary angioedema treatments are associated with side effects, such as pain at the injection site, increased risk of infection, and allergic reactions. These adverse effects can reduce patient adherence, making it challenging for healthcare providers to balance treatment efficacy with patient comfort and safety.
• Complex Treatment Regimens: Many hereditary angioedema therapies require regular administration via injection or infusion, which can be cumbersome for patients. This complexity can discourage adherence to long-term treatments, creating a challenge in ensuring consistent symptom control and attack prevention.
• Challenges in Accurate Diagnosis: Accurate hereditary angioedema diagnosis can be challenging due to its rarity and symptom similarity to other conditions, such as allergies. Misdiagnosis can lead to inappropriate treatment, further complicating patient care and delaying access to effective hereditary angioedema therapies.

Future Opportunities

• Expansion of Prophylactic Treatment Options: The market for prophylactic hereditary angioedema treatments is expanding as patients seek long-term management solutions. Pharmaceutical companies investing in developing and improving preventive therapies can capture a growing market segment focused on reducing attack frequency and improving quality of life.
• Growing Demand for Personalised Medicine: Advances in genetic research offer opportunities to develop personalised hereditary angioedema treatments tailored to individual patient profiles. Personalised therapies that address specific genetic markers and treatment responses can enhance efficacy, providing patients with more targeted and effective care.
• Emerging Markets with Improved Healthcare Access: Emerging markets, particularly in Asia and Latin America, present significant growth opportunities as healthcare access and infrastructure improve. Pharmaceutical companies can expand their reach by offering affordable and accessible hereditary angioedema treatments in these regions, broadening market potential.
• Development of Oral Treatment Options: The development of oral hereditary angioedema treatments is an opportunity to provide more convenient options for patients. Oral medications eliminate the need for injections or infusions, improving patient adherence and potentially capturing a segment of the market seeking simplified treatment regimens.
• Collaborations with Research Institutions: Collaborating with academic and research institutions can accelerate hereditary angioedema treatment development. Partnerships in research and clinical trials facilitate knowledge sharing and resource pooling, helping pharmaceutical companies bring new therapies to market more efficiently.

Hereditary Angioedema Market Trends

The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the market's future direction. These trends are expected to influence the landscape significantly, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.

• Shift Towards Subcutaneous Administration

There is a growing preference for subcutaneous administration of hereditary angioedema treatments, offering patients a more convenient alternative to intravenous options. Subcutaneous therapies allow for self-administration at home, giving patients greater control over their treatment schedule. This method appeals to individuals seeking simplified, user-friendly treatment options that minimise the need for frequent clinic visits and provide greater autonomy in managing their condition.

• Increasing Focus on Prophylactic Therapies

Prophylactic treatments are gaining traction as patients and healthcare providers aim to reduce the frequency of hereditary angioedema attacks. Preventive options, such as C1 esterase inhibitors, are being prioritised for the long-term management of hereditary angioedema. This trend reflects a shift towards proactive care, enabling patients to experience fewer attacks and improved quality of life, while reducing emergency care requirements and overall healthcare costs.

• Advancements in Biologic Therapies

Biologic therapies that target specific proteins involved in hereditary angioedema attacks are becoming more prominent in the market. These therapies provide precise, targeted treatments with fewer side effects compared to traditional options. By focusing on specific pathways, biologics offer innovative solutions for preventing and controlling attacks, attracting patients who seek effective and modern approaches to managing hereditary angioedema.

• Rising Investment in Orphan Drugs

Pharmaceutical companies are increasing investments in orphan drug development to address rare conditions like hereditary angioedema. This trend is driven by regulatory incentives, such as fast-track approvals and extended market exclusivity, as well as high demand for niche treatments. Orphan drug development supports the creation of specialised therapies that meet the specific needs of hereditary angioedema patients, fostering market expansion and innovation.

• Integration of Digital Health Tools

Digital health tools, such as mobile apps for tracking symptoms and medication adherence, are becoming integral to hereditary angioedema management. These tools enable patients to monitor their condition, receive reminders for medication, and log their symptoms, providing valuable data to healthcare providers. The integration of digital tools enhances patient engagement, supports tailored treatment plans, and helps optimise overall care.

• Focus on Patient Education and Support

Pharmaceutical companies are investing in patient education and support programmes to raise awareness about hereditary angioedema, promote early diagnosis, and provide guidance on treatment options. These initiatives empower patients by equipping them with knowledge about their condition, encouraging proactive management. Enhanced patient education leads to better health outcomes, as individuals are more informed and engaged in their treatment journey.

Hereditary Angioedema Market Segmentation

Market Breakup by Drug Class

• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Others

The hereditary angioedema market is segmented by drug class into C1 esterase inhibitors, selective bradykinin B2 receptor antagonists, kallikrein inhibitors, and others. C1 esterase inhibitors help prevent attacks by regulating the complement pathway. Bradykinin receptor antagonists target bradykinin receptors involved in inflammation, while kallikrein inhibitors reduce the frequency and severity of hereditary angioedema attacks by inhibiting kallikrein, an enzyme involved in the attack process. The other segment includes emerging therapies and combination treatments for more comprehensive symptom management.

Market Breakup by Route of Administration

• Intravenous
• Subcutaneous
• Others

The market is further segmented by route of administration into intravenous, subcutaneous, and others. Intravenous options, such as C1 esterase inhibitors, are often used in acute care settings for rapid relief. Subcutaneous treatments offer convenience, allowing patients to self-administer at home. The others segment includes experimental administration methods under research, which may provide new avenues for hereditary angioedema management.

Market Breakup by End User

• Hospitals
• Clinics
• Others

End user segmentation includes hospitals, clinics, and other healthcare settings. Hospitals handle severe hereditary angioedema cases, particularly during acute attacks requiring immediate intervention. Clinics focus on long-term hereditary angioedema management and routine care, administering prophylactic and acute treatments. The others category covers specialised centres and home care settings where patients can receive subcutaneous treatments or engage in remote care management.

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Regionally, the market is segmented into the United States, EU-4 the United Kingdom, Japan, and India. The United States leads the market due to high awareness and advanced healthcare infrastructure. EU-4 and the UK are also significant markets, driven by strong support for rare disease treatment initiatives. Japan demonstrates robust demand as awareness of hereditary angioedema rises, while India presents an emerging market, supported by improving access to healthcare services.

Hereditary Angioedema Market Competitive Landscape

Key players in the hereditary angioedema market include Takeda Pharmaceutical Company, CSL Behring, Pharvaris N.V., BioCryst Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Sanofi S.A., BioMarin Pharmaceutical Inc., Adverum Biotechnologies Inc., and Novartis AG. These companies focus on developing innovative hereditary angioedema treatments, investing in genetic research, and advancing biological therapies to provide effective management options. They are also pursuing strategic collaborations and clinical trials to enhance their offerings, aiming to address unmet patient needs and expand their presence in the rare disease treatment market.

Key Questions Answered in the Report

• What are the primary drivers of growth in the hereditary angioedema market?
• How are advancements in genetic research influencing new treatments for hereditary angioedema?
• What challenges do patients and healthcare providers face with current hereditary angioedema therapies?
• Which regions are expected to see the highest demand for hereditary angioedema treatments?
• How is regulatory support affecting the development of rare disease therapies?
• What role do prophylactic treatments play in managing hereditary angioedema?
• How are digital health tools integrated into hereditary angioedema management for better patient outcomes?
• What trends are emerging in the development of biologic therapies for hereditary angioedema?
• Which drug classes are the most commonly used for hereditary angioedema, and why?
• What strategies are leading companies using to expand their presence in emerging markets?
• How is the demand for subcutaneous administration impacting the hereditary angioedema treatment landscape?
• How do collaborations with research institutions drive innovation in hereditary angioedema therapies?

Key Benefits for Stakeholders

• The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the hereditary angioedema market from 2017-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the hereditary angioedema market.
• The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the hereditary angioedema industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.

This product will be delivered within 5-7 business days.